Menu
Recruiting NCT06261034

A Study of Sex Differences in Neurocirculatory Control

— Observational Obstructive Sleep Apnea

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Obstructive Sleep Apnea. Basic parameters: 20 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Sex Differences in Neurocirculatory Control With Obstructive Sleep Apnea

Overview

The purpose of this study is to investigate potential sex differences in neurocirculatory control of blood pressure in patients with untreated obstructive sleep apnea (OSA).

Primary outcome measures

  • Blood pressure [Time frame: Baseline]
  • Arterial stiffness [Time frame: Baseline]
  • Endothelial function [Time frame: Baseline]
Secondary outcome measures (4)
  • Sympathetic nerve burst frequency [Time frame: Baseline]
  • Sympathetic nerve burst incidence [Time frame: Baseline]
  • Sympathetic nerve burst amplitude (AU) [Time frame: Baseline]
  • Total muscle sympathetic nerve activity (MSNA) [Time frame: Baseline]

Eligibility criteria

Inclusion criteria

  • 20-70 years of age

Exclusion criteria

  • Coronary artery disease
  • Heart failure
  • Pregnancy
  • COPD
  • Diabetes
  • CKD
  • Sleep disorders other than OSA
  • Shift workers
  • Individuals who typically go to sleep after midnight
  • Individuals who traveled across ≥2 time zones within one week of study visits
  • BMI ≥40.0kg/m2
  • Use of nicotine-containing products within the two years preceding study visits
  • Use of allopurinol, proton pump inhibitors, or other medications/supplements which interfere with outcome measures

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • Mayo Clinic in Rochester — Rochester

Identifiers

NCT: NCT06261034 · 23-008765 · 8K12AR084222-15

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗